Effectiveness of Automated Insulin Management Features of the MiniMed^® 640G Sensor-Augmented Insulin Pump

Abstract

Background: Automated insulin management features of the MiniMed® 640G sensor-augmented pump system include suspension in response to predicted low sensor glucose (SG) values (“suspend before low”), suspension in response to existing low SG values (“suspend on low”), and automatic restarting of basal insulin delivery upon SG recovery. The effectiveness of these features was evaluated using CareLink® software data.Methods: Anonymized data from MiniMed 640G system users (n = 4818), MiniMed 530G system users (n = 39,219), and MiniMed Paradigm® Veo™ system users (n = 43,193) who voluntarily uploaded pump and sensor data were retrospectively analyzed. Comparisons were made between days in which system features were enabled at any time and those in which they were not. Comparisons were also made between pump suspension events for which insulin delivery was automatically or manually resumed and between glycemic parameters of users who switched from the MiniMed Paradigm Veo system to the MiniMed 640G system.Results: Days in which the MiniMed 640G “suspend before low” feature was enabled had lower percentages of SG readings ≤70 mg/dL (3.9 mmol/L) or ≥240 mg/dL (13.3 mmol/L) than days when it was not enabled (P < 0.001 for each). Users who switched from the MiniMed Paradigm Veo system to the MiniMed 640G system had fewer excursions below ≤70 mg/dL (P < 0.001) and ≥240 mg/dL (P < 0.001). SG values following automatically resumed pump suspension events recovered more rapidly and had a more stabilized endpoint than following manually resumed events.Conclusions: Automated insulin management features of the MiniMed 640G system can reduce the frequency of both high and low SG values and help stabilize SG after resumption of insulin delivery.

Clinical Use of Continuous Glucose Monitoring in Adults with Type 1 Diabetes

“…Duration of night time hypoglycemia was significantly lower in those patients with suspend on low feature activated (0.4 -0.8 vs. 0.2 -0.5 h; P < 0.001); and lower avain when using the suspend before low feature (0.4 -1.0 vs. 0.1 -0.1 h/night; P < 0.001). 35 …”

CGM, Pregnancy, and Remote Monitoring

“…Remote monitoring includes the ability to see glucose meter data, CGM data as trends or daily patterns, and insulin pump downloads. Regarding CGM remote monitoring, some companies have software specifically for their products, such as CareLink and CareLink Pro for Medtronic products [54][55][56][57][58][59] and Studio, Share, and Clarity for Dexcom products. 60,61 Other programs can download multiple devices and view data in one system, such as Glooko, [61][62][63] Tidepool Blip, 61,64 and Diasend.…”

“…61,65 Software and online programs have been used in remote or retrospective monitoring of glucose data in nonpregnant populations. [55][56][57][58][59][66][67][68] One CGM system was evaluated with concurrent remote monitoring at children's diabetes camps. On control nights of CGM use, subjects (n = 57) could hear hypoglycemia alarms, but on intervention nights, only medical personnel received alarms through remote monitoring.…”

Evaluation of the quality of life and satisfaction with the therapy in patients with type 1 diabetes — is Medtronic MiniMed 640G system able to improve it? Preliminary insights

“…In the last 3 years, there have been many excellent reviews of progress made in the field of artificial pancreas research [18][19][20][21]. Numerous researches confirm that sensor-augmented pump therapy with automated insulin suspension reduces the rate of hypoglycemia in patients with type 1 diabetes [22,23]. Innovative MiniMed 640G system completely proves this statement.…”